Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.

Lionel Adès, Raphael Itzykson, Pierre Fenaux

Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Service d'hématologie clinique, Paris 13 university, Bobigny, France.

Seminars in hematology 2012 Oct

filter terms:

Azacitidine (AZA) improves long-term outcomes of higher-risk myelodysplastic syndrome (MDS) and is now the reference frontline therapy of higher-risk MDS not eligible for allogeneic stem cell transplant. Notably, in a phase III randomized trial, AZA significantly prolonged overall survival (OS) compared to conventional care regimens, in all cytogenetic subgroups. Nevertheless, further improvement of outcome for those patients is warranted, partly by researching for better prognostic factors of response to AZA, and also by developing new therapeutic strategies, in particular by combining AZA and other drugs known to have an effect in MDS. We review the prognostic factors of response and survival of patients treated with AZA, the combination of AZA with other drugs, and the use of AZA in specific situations, such as therapy-related MDS, chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), and in MDS/AML occurring in the course of myeloproliferative neoplasms (MPN). Copyright © 2012 Elsevier Inc. All rights reserved.

Citation

Lionel Adès, Raphael Itzykson, Pierre Fenaux. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine. Seminars in hematology. 2012 Oct;49(4):323-9